Year None202420232022202120202019 Jul 23, 2024 Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Jul 22, 2024 Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL Jul 09, 2024 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Ad Jul 09, 2024 Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis Jul 03, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 10, 2024 Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderat Jun 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 05, 2024 Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing A Jun 03, 2024 Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 9 of 34